NFKB1 and cancer: Further, a recent study showed that the potential anti-cancer drug, Shikonin, could inhibit PD-L1 glycosylation via the NF-κB/STAT3 and NF-κB/CSN5 (COP9 signalosome subunit 5) pathways in pancreatic cancer cells.140 PD-L1 glycosylation may also impact its specific recognition by antibodies, thereby diminishing the effectiveness of monoclonal antibody drugs, and preventing diagnosis by disrupting antibody-dependent detection.